Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Serotype A Botulinum Toxin
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Healis Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Healis Therapeutics Shares Phase III Topline Results for CKDB-501A Glabellar Injections
Details : CKDB-501A (serotype A botulinum toxin) is a novel BoNT/A neuromodulator protein. It is being evaluated for the treatment of moderate-to-severe glabellar lines.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
February 27, 2024
Lead Product(s) : Serotype A Botulinum Toxin
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Healis Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CKDB-501
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : Healis Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Healis Announces Supply Agreement With CKD Bio To Develop CKDB-501
Details : Under the agreement, Healis intends to develop CKDB-501, a neuromodulator Serotype A botulinum toxin (BoNT/A) protein, for Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD).
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
February 01, 2024
Lead Product(s) : CKDB-501
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : Healis Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : CKDB-501A
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 07, 2023
Lead Product(s) : CKDB-501A
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CKDB-501B
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 23, 2022
Lead Product(s) : CKDB-501B
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CKDB-501A
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of CKDB-501A in Subjects With Post-stroke Upper Limb Spasticity
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 19, 2022
Lead Product(s) : CKDB-501A
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CKDB-501A
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 23, 2022
Lead Product(s) : CKDB-501A
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable